New CDMO business development leader joins BioHarvest Sciences (NASDAQ: BHST)

Rhea-AI Filing Summary

BioHarvest Sciences Inc. has appointed Nedira Salzman-Frenkel as Vice President of Business Development for its contract development and manufacturing organization (CDMO) division. Her role focuses on sourcing and managing new contracts across pharmaceutical, nutraceutical, nutrition, and cosmetic markets as the company grows this business.

The company states that Salzman-Frenkel will work closely with senior leadership to help deliver revenue targets and support the launch of a new facility next year. Her background includes senior business development roles in biotech and contract research, where she previously secured substantial CRO contracts and licensing arrangements.

Key Figures

CRO contracts secured: $30 million

1 metrics

CRO contracts secured $30 million Previously secured at Salzman Group across multiple industries

Key Terms

Botanical Synthesis, contract development and manufacturing organization (CDMO), forward-looking statements, Phase 3 clinical development, +1 more

5 terms

Botanical Synthesis technical

"a leader in Botanical Synthesis technology and sustainable plant-based molecule development"

Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.

contract development and manufacturing organization (CDMO) financial

"BioHarvest’s contract development and manufacturing organization (CDMO) business"

A contract development and manufacturing organization (CDMO) is a company that develops and produces drugs, vaccines or other medical products for other firms, handling steps from formulation and testing to large-scale manufacturing and quality control. Investors care because CDMOs function like outsourced specialized factories and development partners: their revenue grows when many clients need production capacity or development expertise, so their performance signals broader industry demand and is tied to regulatory approvals and client programs.

forward-looking statements regulatory

"This news release contains forward-looking statements within the meaning of applicable securities laws."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Phase 3 clinical development medical

"a binding licensing term-sheet with a top global pharmaceutical company for Phase 3 clinical development."

Phase 3 clinical development is the large, late-stage testing of a medical treatment in diverse patient populations to confirm whether it works, to gather more safety information, and to compare it with current standard treatments. Think of it like a final dress rehearsal before a product’s public launch: regulators rely on Phase 3 results to decide approval, so clear success can sharply increase a product’s commercial value while failure can materially reduce a company’s prospects.

contract research organization (CRO) technical

"a global pharmaceutical and contract research organization (CRO) that was focused on pre-clinical and clinical development"

A contract research organization (CRO) is an outside company that runs scientific and regulatory work for drug, biotech, and medical-device developers—such as running clinical trials, lab testing, and preparing paperwork for regulators. Investors care because CROs affect how quickly and cheaply a product moves toward approval: they’re like specialized contractors whose capacity, expertise, and costs can speed development, reduce risk, and influence sponsors’ spending and timelines.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	News Release dated May 12, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: May 14, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

 

BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division

Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships

Vancouver, British Columbia and Rehovot, Israel - May 12, 2026 - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel’s role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest’s contract development and manufacturing organization (CDMO) business.

 

Photo: Ms. Nedira Salzman-Frenkel

“We are pleased to welcome Nedira to our team to lead business development for BioHarvest’s CDMO, aligned with our strategy of building long-term partnerships with customers,” commented Dr. Zaki Rakib. “Nedira brings over a decade of experience in the life sciences industry, including securing contracts with pharmaceutical companies and other related sectors. She has strong experience leading licensing deals, operational scaling, and building cross-functional teams. Nedira will work closely with me to deliver on our revenue targets, in line with our anticipated growth and the launch of our new facility next year.”

Previously, Ms. Salzman-Frenkel was Vice President of Business Development at an Israeli biotech, where she spearheaded BD efforts, resulting in a binding licensing term-sheet with a top global pharmaceutical company for Phase 3 clinical development. Prior to this, Ms. Salzman-Frenkel was CEO of the Salzman Group, a global pharmaceutical and contract research organization (CRO) that was focused on pre-clinical and clinical development of novel, small-molecule therapeutics, while providing services to the pharmaceutical, medical device, and agrochemical industries. During her tenure, Ms. Salzman-Frenkel secured approximately $30 million dollars in CRO contracts across these industries. Prior to this, Ms. Salzman-Frenkel co-founded Beetlebung Pharma Ltd. and Solviva, as well as led business development efforts at Salzman Capital Ventures, Ltd., a firm providing full-service pharmaceutical support, custom laboratory research and development, and drug development consultation.

Ms. Salzman-Frenkel commented, “I am excited to join BioHarvest at such an important stage, particularly as demand continues to increase for innovative and sustainable CDMO solutions. BioHarvest’s Botanical Synthesis platform represents a differentiated approach to the development and manufacturing of plant-

derived bioactive compounds, and I look forward to expanding strategic partnerships and commercial opportunities across multiple industries. Leveraging my experience in drug development and business strategy, I aim to drive BioHarvest’s continued growth.”

Ms. Salzman-Frenkel has a Master of Business Administration from Tel Aviv University, a Master of Science in Biochemistry from Hebrew University of Jerusalem and a Bachelor of Science in Life Sciences from Ben Gurion University.

About BioHarvest

BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management’s current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance that the company will obtain expanded business partnerships and commercial opportunities, and readers are cautioned that additional future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company’s SEC filings, available at http://www.sec.gov.

BioHarvest Company Contact:

Dave Ryan, VP Investor Relations

(604) 622-1186

info@bioharvest.com

Investor Relations Contact:

Chuck Padala, Managing Director

LifeSci Advisors

chuck@lifesciadvisors.com

FAQ

What executive change did BioHarvest Sciences (BHST) announce in this Form 6-K?

BioHarvest Sciences appointed Nedira Salzman-Frenkel as Vice President of Business Development for its CDMO division. She will lead efforts to source and manage new customer contracts across pharmaceuticals, nutraceuticals, nutrition, and cosmetics, aligning with the company’s strategy to build long-term development and manufacturing partnerships.

How does the new business development role support BioHarvest Sciences (BHST) CDMO strategy?

The new Vice President of Business Development role is designed to secure and manage long-term CDMO partnerships. It focuses on expanding contracts across multiple industries, supporting BioHarvest’s plan to grow its botanical synthesis-based services and help meet revenue goals as a new facility comes online next year.

What relevant experience does Nedira Salzman-Frenkel bring to BioHarvest Sciences (BHST)?

Nedira Salzman-Frenkel brings over a decade of life sciences business development experience, including senior roles in biotech and CROs. She has led licensing deals, operational scaling, and cross-functional teams, and previously helped secure approximately $30 million in CRO contracts across pharmaceutical and related industries.

Which markets will BioHarvest Sciences (BHST) target with its CDMO business under the new VP?

Under the new Vice President of Business Development, BioHarvest plans to target pharmaceutical, nutraceutical, nutrition, and cosmetic markets. The focus is on leveraging its Botanical Synthesis platform to provide innovative, sustainable development and manufacturing solutions for plant-derived bioactive compounds across these customer segments.

What is BioHarvest Sciences (BHST) Botanical Synthesis platform mentioned in the filing?

BioHarvest’s Botanical Synthesis platform is a patented technology used to grow plant-based compounds without cultivating the full plant. The company applies this platform both in its CDMO services for customers seeking novel plant-based molecules and in its own proprietary nutraceutical and health and wellness product offerings.

Does this BioHarvest Sciences (BHST) filing include any forward-looking statements?

Yes, the news release contains forward-looking statements about expected CDMO partnerships, revenue potential, and future contracts. It cautions that additional agreements may not progress or become commercialized, and that increased revenue would also bring higher costs, so profitability is not guaranteed for these initiatives.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWS RELEASE DATED MAY 12, 2026 9.2 KB